Rezolute, Inc. (RZLT)
| Market Cap | 344.74M +15.5% |
| Revenue (ttm) | n/a |
| Net Income | -81.49M |
| EPS | -0.80 |
| Shares Out | 104.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,503,674 |
| Open | 3.270 |
| Previous Close | 3.270 |
| Day's Range | 3.220 - 3.460 |
| 52-Week Range | 1.070 - 11.457 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 5.88 (+78.18%) |
| Earnings Date | May 12, 2026 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for RZLT stock is "Buy." The 12-month stock price target is $5.88, which is an increase of 78.18% from the latest price.
News
Rezolute price target raised to $10 from $4 at Maxim
Maxim raised the firm’s price target on Rezolute (RZLT) to $10 from $4 and keeps a Buy rating on the shares after its Q3 results. The company’s Ersodetug, which had…
Rezolute reports Q3 EPS (16c), consensus (17c)
Cash, cash equivalents and investments in marketable securities were $120.3M as of March 31, compared with $167.9M as of June 30, 2025.
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all for...
Rezolute Earnings release: Q3 2026
Rezolute released its Q3 2026 earnings on May 12, 2026, summarizing the period's financial results.
Rezolute Quarterly report: Q3 2026
Rezolute has published its Q3 2026 quarterly earnings report on May 12, 2026.
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all for...
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026
Rezolute (RZLT) announced that expanded analyses from the Phase 3 sunRIZE study of ersodetug in patients with congenital HI were presented at the Pediatric Endocrine Society 2026 Annual Meeting. The…
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared t...
Rezolute, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rezolute, Inc., (“Rezolute" or the "Company") (NASDAQ: RZLT) investors that the firm has initiated an investigation into po...
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on March 30, 2026.
Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI
As previously reported, Wedbush analyst Yun Zhong upgraded Rezolute (RZLT) to Outperform from Neutral with a price target of $5, up from $2, based on the update following a Type…
Rezolute upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Rezolute (RZLT) to Outperform from Neutral with a price target of $5, up from $2.
Rezolute provides update on sunRIZE study following Type B meeting with FDA
Rezolute (RZLT) announced outcomes from an in-person Type B meeting with the FDA held, related to sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy stud...
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all f...
Rezolute to Participate in the Citizens Life Sciences Conference
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all f...
Rezolute management to meet with Maxim
Meeting to be held in Miami on March 11 hosted by Maxim.
Rezolute reports Q2 EPS (22c), consensus (18c)
Cash, cash equivalents and investments in marketable securities were $132.9M as of December 31, 2025, compared with $167.9M as of June 30, 2025.
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all fo...
Rezolute Quarterly report: Q2 2026
Rezolute has published its Q2 2026 quarterly earnings report on February 12, 2026.
Rezolute Earnings release: Q2 2026
Rezolute released its Q2 2026 earnings on February 12, 2026, summarizing the period's financial results.
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all fo...
Rezolute price target raised to $2 from $1 at Wedbush
Wedbush raised the firm’s price target on Rezolute (RZLT) to $2 from $1 and keeps a Neutral rating on the shares. The firm notes the company reported PK/PD data and…
Rezolute shares findings from Expanded Access Program in tumor HI
Over the past two years, Rezolute (RZLT) has collaborated with investigators across the United States and in Europe to provide ersodetug to more than a dozen patients with severe and…